Urology · page 3

PSMA radioligand therapy moves earlier: PSMAddition meets its endpoint in hormone-sensitive disease

Adding lutetium-177 PSMA-617 to ADT and an androgen receptor pathway inhibitor cut radiographic progression by 28% in metastatic hormone-sensitive prostate cancer, dose-escalated radiotherapy shows a widening benefit at ten years, and a smaller ureteric stent is more comfortable but falls out more often.